Etzion S, Kedes L H, Kloner R A, Leor J
Neufeld Cardiac Research Institute, Tel-Aviv University, Sheba Medical Center, Tel-Hashomer, Israel.
Am J Cardiovasc Drugs. 2001;1(4):233-44. doi: 10.2165/00129784-200101040-00002.
Cardiomyocytes are terminally differentiated and are unable to proliferate in response to injury. Genetic modulation, cell transplantation and tissue engineering promise a revolutionary approach for myocardial regeneration and tissue repair after myocardial injury. Current data derived from animal models suggest that it may be possible to treat heart failure by inserting genetic materials or myogenic cells into injured myocardium. Success with animal models has raised the hope for new treatment after heart attacks and could prove an alternative to transplantation, particularly in elderly patients for whom there is often a lack of donor hearts. This exciting research, however, still faces significant difficulties before it can develop into a clinical therapeutic tool and many challenges need to be overcome before cell transplantation, gene therapy and tissue engineering can be considered efficient, therapeutic strategies for myocardial regeneration.
心肌细胞是终末分化细胞,受伤后无法增殖。基因调控、细胞移植和组织工程有望为心肌损伤后的心肌再生和组织修复带来革命性的方法。来自动物模型的现有数据表明,通过将遗传物质或肌源性细胞植入受损心肌来治疗心力衰竭或许是可行的。动物模型实验的成功为心脏病发作后的新治疗方法带来了希望,并且可能成为心脏移植的替代方案,尤其是对于常常缺乏供体心脏的老年患者。然而,这项振奋人心的研究在发展成为临床治疗手段之前仍面临重大困难,在细胞移植、基因治疗和组织工程能够被视为有效的心肌再生治疗策略之前,还有许多挑战需要克服。